Company intelligence / Profile preview
Hengye Biotech
Quzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Zhejiang Hengye Pharmaceutical (Hengye Biopharma) is a clinical-stage biotechnology company specializing in recombinant protein drugs and enzymes. Its lead candidate, HY-001 (PEG-uricase), is a long-acting recombinant urate oxidase currently in Phase 2 development for chronic refractory gout and hyperuricemia. The company also develops recombinant human hyaluronidase and other enzyme-based therapies for metabolic and oncology-related indications.
- Therapeutic areas
- RheumatologyMetabolic Disorders
- Modalities
- Recombinant proteinEnzymePEGylated proteinProtein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hengye Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hengye Biotech.